These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Park SJ, Ryu MH, Ryoo BY, Park YS, Sohn BS, Kim HJ, Kim CW, Kim KH, Yu CS, Yook JH, Kim BS, Kang YK. Ann Surg Oncol; 2014 Dec; 21(13):4211-7. PubMed ID: 24980089 [Abstract] [Full Text] [Related]
23. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease. Cao H, Zhang Y, Wang M, Shen DP, Sheng ZY, Ni XZ, Wu ZY, Liu Q, Shen YY, Song YY. Chin Med J (Engl); 2010 Jan 20; 123(2):131-6. PubMed ID: 20137358 [Abstract] [Full Text] [Related]
24. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial. Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG. J Med Econ; 2013 Sep 20; 16(9):1106-19. PubMed ID: 23808902 [Abstract] [Full Text] [Related]
27. The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour. Machlenkin S, Pinsk I, Tulchinsky H, Ziv Y, Sayfan J, Duek D, Rabau M, Walfisch S. Colorectal Dis; 2011 Oct 20; 13(10):1110-5. PubMed ID: 21040362 [Abstract] [Full Text] [Related]
28. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, Krawczyk M, Ruka W. J Surg Oncol; 2006 Mar 15; 93(4):304-11. PubMed ID: 16496358 [Abstract] [Full Text] [Related]
30. [New surgical approaches to localized and advanced gastrointestinal stromal tumors (GIST)]. Bonvalot S, Honoré C. Bull Acad Natl Med; 2012 Mar 15; 196(4-5):855-60; discussion 860. PubMed ID: 23550448 [Abstract] [Full Text] [Related]
31. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection. Tirumani SH, Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH, Raut CP. Eur J Surg Oncol; 2014 Apr 15; 40(4):420-8. PubMed ID: 24238762 [Abstract] [Full Text] [Related]
32. [Clinical analysis of imatinib in patients with advanced gastrointestinal stromal tumor]. Zhang XH, Wu H, He YL, Ma JP, Chen CQ, Xu JB, Cai SR, Han FH, Zhan WH. Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Mar 15; 15(3):243-6. PubMed ID: 22454169 [Abstract] [Full Text] [Related]
33. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence]. Li J, Dang YZ, Gao J, Shen L. Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar 15; 16(3):216-20. PubMed ID: 23536338 [Abstract] [Full Text] [Related]
37. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)]. Miyake M, Takeda Y, Hasuike Y, Kashiwazaki M, Mishima H, Ikenaga M, Mano M, Takada Y, Hirota S, Tsujinaka T. Gan To Kagaku Ryoho; 2004 Oct 15; 31(11):1791-4. PubMed ID: 15553717 [Abstract] [Full Text] [Related]